BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15364199)

  • 1. Functions of myc:max in the control of cell proliferation and tumorigenesis.
    Hurlin PJ; Dezfouli S
    Int Rev Cytol; 2004; 238():183-226. PubMed ID: 15364199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function of the c-Myc oncogenic transcription factor.
    Dang CV; Resar LM; Emison E; Kim S; Li Q; Prescott JE; Wonsey D; Zeller K
    Exp Cell Res; 1999 Nov; 253(1):63-77. PubMed ID: 10579912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Myc-interacting proteins: a second Myc network emerges.
    Sakamuro D; Prendergast GC
    Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
    Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
    Larsson LG; Bahram F; Burkhardt H; Lüscher B
    Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-target recognition among members of the myc superfamily and implications for oncogenesis.
    O'Hagan RC; Schreiber-Agus N; Chen K; David G; Engelman JA; Schwab R; Alland L; Thomson C; Ronning DR; Sacchettini JC; Meltzer P; DePinho RA
    Nat Genet; 2000 Feb; 24(2):113-9. PubMed ID: 10655054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
    Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
    Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
    Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression by the Mad(Mxi1)-Sin3 complex.
    Schreiber-Agus N; DePinho RA
    Bioessays; 1998 Oct; 20(10):808-18. PubMed ID: 9819568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.
    Wiener Z; Ontsouka EC; Jakob S; Torgler R; Falus A; Mueller C; Brunner T
    Exp Cell Res; 2004 Sep; 299(1):227-35. PubMed ID: 15302589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc.
    FitzGerald MJ; Arsura M; Bellas RE; Yang W; Wu M; Chin L; Mann KK; DePinho RA; Sonenshein GE
    Oncogene; 1999 Apr; 18(15):2489-98. PubMed ID: 10229200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.